Public Health Importance of Invasive Methicillin-sensitive Staphylococcus aureus Infections: Surveillance in 8 US Counties, 2016.
MSSA
MSSA burden
methicillin-sensitive Staphylococcus aureus
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
03 03 2020
03 03 2020
Historique:
received:
12
02
2019
accepted:
15
04
2019
pubmed:
28
6
2019
medline:
7
1
2021
entrez:
28
6
2019
Statut:
ppublish
Résumé
Public health and infection control prevention and surveillance efforts in the United States have primarily focused on methicillin-resistant Staphylococcus aureus (MRSA). We describe the public health importance of methicillin-susceptible S. aureus (MSSA) in selected communities. We analyzed Emerging Infections Program surveillance data for invasive S. aureus (SA) infections (isolated from a normally sterile body site) in 8 counties in 5 states during 2016. Cases were considered healthcare-associated if culture was obtained >3 days after hospital admission; if associated with dialysis, hospitalization, surgery, or long-term care facility (LTCF) residence within 1 year prior; or if a central venous catheter was present ≤2 days prior. Incidence per 100 000 census population was calculated, and a multivariate logistic regression model with random intercepts was used to compare MSSA risk factors with those of MRSA. Invasive MSSA incidence (31.3/100 000) was 1.8 times higher than MRSA (17.5/100 000). Persons with MSSA were more likely than those with MRSA to have no underlying medical conditions (adjusted odds ratio [aOR], 2.06; 95% confidence interval [CI], 1.26-3.39) and less likely to have prior hospitalization (aOR, 0.70; 95% CI, 0.60-0.82) or LTCF residence (aOR, 0.37; 95% CI, 0.29-0.47). MSSA accounted for 59.7% of healthcare-associated cases and 60.1% of deaths. Although MRSA tended to be more closely associated with healthcare exposures, invasive MSSA is a substantial public health problem in the areas studied. Public health and infection control prevention efforts should consider MSSA prevention in addition to MRSA.
Sections du résumé
BACKGROUND
Public health and infection control prevention and surveillance efforts in the United States have primarily focused on methicillin-resistant Staphylococcus aureus (MRSA). We describe the public health importance of methicillin-susceptible S. aureus (MSSA) in selected communities.
METHODS
We analyzed Emerging Infections Program surveillance data for invasive S. aureus (SA) infections (isolated from a normally sterile body site) in 8 counties in 5 states during 2016. Cases were considered healthcare-associated if culture was obtained >3 days after hospital admission; if associated with dialysis, hospitalization, surgery, or long-term care facility (LTCF) residence within 1 year prior; or if a central venous catheter was present ≤2 days prior. Incidence per 100 000 census population was calculated, and a multivariate logistic regression model with random intercepts was used to compare MSSA risk factors with those of MRSA.
RESULTS
Invasive MSSA incidence (31.3/100 000) was 1.8 times higher than MRSA (17.5/100 000). Persons with MSSA were more likely than those with MRSA to have no underlying medical conditions (adjusted odds ratio [aOR], 2.06; 95% confidence interval [CI], 1.26-3.39) and less likely to have prior hospitalization (aOR, 0.70; 95% CI, 0.60-0.82) or LTCF residence (aOR, 0.37; 95% CI, 0.29-0.47). MSSA accounted for 59.7% of healthcare-associated cases and 60.1% of deaths.
CONCLUSIONS
Although MRSA tended to be more closely associated with healthcare exposures, invasive MSSA is a substantial public health problem in the areas studied. Public health and infection control prevention efforts should consider MSSA prevention in addition to MRSA.
Identifiants
pubmed: 31245810
pii: 5477381
doi: 10.1093/cid/ciz323
pmc: PMC7902232
mid: NIHMS1667536
doi:
Substances chimiques
Methicillin
Q91FH1328A
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1021-1028Subventions
Organisme : NCEZID CDC HHS
ID : U50 CK000198
Pays : United States
Organisme : NCEZID CDC HHS
ID : U50 CK000199
Pays : United States
Organisme : NCEZID CDC HHS
ID : U50 CK000196
Pays : United States
Organisme : NCEZID CDC HHS
ID : U50 CK000201
Pays : United States
Organisme : NCEZID CDC HHS
ID : U50 CK000204
Pays : United States
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Références
Clin Infect Dis. 2003 Jan 1;36(1):53-9
pubmed: 12491202
Infect Control Hosp Epidemiol. 2008 Oct;29 Suppl 1:S62-80
pubmed: 18840090
Pediatr Infect Dis J. 2002 Oct;21(10):910-7
pubmed: 12394811
Clin Infect Dis. 2017 Mar 1;64(5):597-604
pubmed: 28362911
JAMA Intern Med. 2013 Nov 25;173(21):1970-8
pubmed: 24043270
JAMA. 2017 Jul 25;318(4):329-330
pubmed: 28654976
Jt Comm J Qual Patient Saf. 2007 Aug;33(8):477-84
pubmed: 17724944
J Infect Dis. 2001 Oct 15;184(8):1029-34
pubmed: 11574918
Pediatrics. 2012 Apr;129(4):e914-22
pubmed: 22412036
BMJ. 2006 Aug 5;333(7562):281
pubmed: 16798756
Pediatrics. 2013 Oct;132(4):e817-24
pubmed: 24062373
PLoS One. 2011 Apr 13;6(4):e18217
pubmed: 21533238
J Infect Dis. 2008 Aug 1;198(3):336-43
pubmed: 18522502
Infect Control Hosp Epidemiol. 2018 Dec;39(12):1487-1490
pubmed: 30370879
N Engl J Med. 2019 Feb 14;380(7):638-650
pubmed: 30763195
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301
pubmed: 27573805
Clin Infect Dis. 2008 Mar 15;46(6):799-806
pubmed: 18266610
J Pediatric Infect Dis Soc. 2012 Sep;1(3):200-11
pubmed: 23687577
Clin Infect Dis. 2007 Feb 15;44(4):471-82
pubmed: 17243048
JAMA. 2007 Oct 17;298(15):1763-71
pubmed: 17940231
Epidemiol Infect. 2011 Mar;139(3):419-29
pubmed: 20513251
Clin Infect Dis. 2011 Feb 1;52(3):e18-55
pubmed: 21208910
Clin Infect Dis. 2013 Nov;57(10):1393-400
pubmed: 23964088
Emerg Infect Dis. 2019 Jan;25(1):171-174
pubmed: 30561319